According to the
Public Health Scotland weekly report published Feb 09, 2022:
During the height of the Omicron surge:
Table 13 on page 37 shows that for each of the three weeks spanning Jan 08 2022 through Jan 28 2022 people with 2 doses were more likely than the unvaccinated to be hospitalized because of Covid.
Table 15 on page 43 shows that for each of the four weeks spanning Jan 01 2022 through Feb 04 2022 people with 2 doses were more likely to die because of Covid than the unvaccinated.
See clickable thumbnails below.
From page 29:
Quote:
Vaccine effectiveness wanes over time
COVID-19 vaccine effectiveness wanes over time. Within the first and second dose population, there will be a number of individuals that will have exceeded the recommended time for their next vaccine dose. These people may be more susceptible to a severe outcome and could result in higher COVID-19 case, hospitalisation and death rates in the first and second dose vaccine groups. For example, some of the older individuals who have exceeded the recommended time will have not received their next vaccine dose because of frailty or ill health. They are, therefore, more likely to be hospitalised or die if they get COVID-19.
|
The
wanes over time link leads to a page on the Public Health England site where you can find links to weekly vaccine surveillance reports.
COVID-19 vaccine surveillance report: 3 February 2022 (week 5):
https://assets.publishing.service.go...t_-_week_5.pdf
From page 3 at the above link:
Quote:
Vaccine effectiveness
Several studies of vaccine effectiveness have been conducted in the UK against different COVID-19 variants. Vaccine effectiveness against symptomatic disease with the Omicron variant is substantially lower than against the Delta variant, with rapid waning. However, protection against hospitalisation remains high, particularly after 3 doses.
|
From page 9 at the above link:
Quote:
Effectiveness against hospitalisation
Several studies have estimated vaccine effectiveness against hospitalisation in older ages, all of which indicate higher levels of protection against hospitalisation with all vaccines against the Alpha and Delta variants (6, 7, 8, 9). Vaccine effectiveness against hospitalisation with the Omicron variant has been estimated using a test-negative case control study design (Figure 2). Two doses of either AstraZeneca (ChAdOx1-S) or Pfizer (BNT162b2) vaccines was associated with a vaccine effectiveness of approximately 25 to 35% against hospitalisation following infection with the Omicron variant, after 25+ weeks. After a Pfizer booster (after either primary vaccination course), vaccine effectiveness against hospitalisation started at around 90% dropping to around 75% after 10 to 14 weeks. After a Moderna booster (mRNA-1273) (after either primary vaccination course), vaccine effectiveness against hospitalisation was 90 to 95% up to 9 weeks after vaccination.
|
From page 12 at the above link:
Quote:
Effectiveness against mortality
High levels of protection (over 90%) are also seen against mortality with all 3 vaccines and against both the Alpha and Delta variants with relatively limited waning (6, 10, 11). Vaccine effectiveness against mortality with the Omicron variant has been estimated for those aged 50 years and older by combining the risk of becoming a symptomatic case with the risk of death among symptomatic cases in vaccinated (all vaccines combined) compared to unvaccinated individuals (Table 1). At 25+ weeks following the second dose, vaccine effectiveness was around 60% while at 2 or more weeks following a booster vaccine effectiveness was 95% against mortality.
|
-jp
.
